Use of GAL3 antagonist for treatment of depression and/or...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C548S483000, C548S484000

Reexamination Certificate

active

07465750

ABSTRACT:
This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

REFERENCES:
patent: 4874687 (1989-10-01), Itabashi et al.
patent: 4921503 (1990-05-01), Anderson et al.
patent: 4946956 (1990-08-01), Wheeler et al.
patent: 5017466 (1991-05-01), Kobayashi et al.
patent: 5198461 (1993-03-01), Watjen et al.
patent: 5547949 (1996-08-01), Maho et al.
patent: 5728704 (1998-03-01), Mylari et al.
patent: 5801150 (1998-09-01), Caillot et al.
patent: 5840893 (1998-11-01), Bukrinsky et al.
patent: 6287788 (2001-09-01), Bard et al.
patent: 6329197 (2001-12-01), Bard et al.
patent: 6368812 (2002-04-01), Bard et al.
patent: 7081470 (2006-07-01), Konkel et al.
patent: 7166635 (2007-01-01), Konkel et al.
patent: 7220775 (2007-05-01), Blackburn
patent: 2003/0027254 (2003-02-01), Bard et al.
patent: 2003/0118096 (2003-06-01), Bard et al.
patent: 0359465 (1990-03-01), None
patent: 0363002 (1990-04-01), None
patent: 0640599 (1995-03-01), None
patent: 0667340 (1995-08-01), None
patent: 0788890 (1997-08-01), None
patent: 0945442 (1999-09-01), None
patent: 0972770 (2000-01-01), None
patent: 1477349 (1977-06-01), None
patent: 11158073 (1977-06-01), None
patent: 075449 (2002-03-01), None
patent: WO9325539 (1993-12-01), None
patent: WO9815570 (1998-04-01), None
patent: WO9941253 (1999-08-01), None
patent: WO9950250 (1999-10-01), None
patent: WO9965875 (1999-12-01), None
patent: WO002865 (2000-01-01), None
El-Ezbawy et al., Caplus Abstract 112:178540, 1990.
Hokfelt, T. et al., “Galanin and NPY, Two Peptides with Multiple Putative Roles in the Nervous System”, Horm. Metab. res. (1999);31:330-334.
Razani, H. et al., Intraventricular Galanin Produces a Time-Dependent Modulation of 5-HT1A in the Dorsal Raphe of the Rat:, Neuropharmacology and Neurotoxicology (2000) 11(18):3943-3948.
U.S. Serial No. 10/214,873 (Konkel et al.), filed Aug. 7, 2002.
U.S. Serial No. 10/066,175, filed Jan. 31, 2002.
Bionet Research Ltd., catalog #11L-312S(1-Phenyl-3-{[3-(trifluoromethyl)phenyl]limino}-1,3-dihydro-2H-indol-2-on3).
U.S. Serial No. 10/006,343,, filed Dec. 3, 2001.
U.S. Serial No. 10/007,132, filed Dec. 3, 2001.
Chemical Abstracts Registry No. 61038-64-0, 2002.
Chemical Abstracts Registry No. 41230-77-7, 2002.
Chemical Abstracts Registry No. 130186-15-1, 2002.
Chemical Abstracts Registry No. 130186-16-2, 2002.
Chemical Abstracts Registry No. 130186-17-3, 2002
Chemical Abstracts Registry No. 130186-18-4, 2002.
Chemical Abstracts Registry No. 130186-21-9, 2002.
Chemical Abstracts Registry No. 130270-13-2, 2002.
Chemical Abstracts Registry No. 133939-75-0, 2002.
Chemical Abstracts Registry No. 56984-58-8, 2002.
Chemical Abstracts Registry No. 77910-42-0, 2002.
Chemical Abstracts Registry No. 70010-41-2, 2002.
Chemical Abstracts Registry No. 189264-35-5, 2002.
Chemical Abstracts Registry No. 88291-04-7, 2002.
Chemical Abstracts Registry No. 88291-07-0, 2002.
Chemical Abstracts Registry No. 154118-05-5, 2002.
Chemical Abstracts Registry No. 155717-81-0, 2002.
Chemical Abstracts Registry No. 155717-82-1, 2002.
Chemical Abstracts Registry No. 159967-24-5, 2002.
Chemical Abstracts Registry No. 138601-94-2, 2002.
Chemical Abstracts Registry No. 136647-69-3, 2002.
Chemical Abstracts Registry No. 136647-72-8, 2002.
Chemical Abstracts Registry No. 77297-28-0, 2002.
Chemical Abstracts Registry No. 43002-26-2, 2002.
Chemical Abstracts Registry No. 303984-69-2, 2002.
Chemical Abstracts Registry No. 122725-53-5, 2002.
Chemical Abstracts Registry No. 122803-89-8, 2002.
Chemical Abstracts Registry No. 303149-10-2, 2002.
Chemical Abstracts Registry No. 303149-08-8, 2002.
Chemical Abstracts Registry No. 303149-06-6, 2002.
Chemical Abstracts Registry No. 303984-47-6, 2002.
Chemical Abstracts Registry No. 303149-14-6, 2002.
Chemical Abstracts Registry No. 303149-12-4, 2002.
Chemical Abstracts Registry No. 303984-51-2, 2002.
Chemical Abstracts Registry No. 303984-49-8, 2002.
Chemical Abstracts Registry No. 303984-48-7, 2002.
Chemical Abstracts Registry No. 303984-52-3, 2002.
Chemical Abstracts Registry No. 303984-60-3, 2002.
Chemical Abstracts Registry No. 303984-61-4, 2002.
Chemical Abstracts Registry No. 303984-62-5, 2002.
Chemical Abstracts Registry No. 33984-68-1, 2002.
English Language Abstract for Japanese Patent No. JP 11158073, 1977.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Use of GAL3 antagonist for treatment of depression and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of GAL3 antagonist for treatment of depression and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of GAL3 antagonist for treatment of depression and/or... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4031749

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.